HUTCHMED (China) Limited (HCM) 10-Year Financial Performance & Capital Metrics

HCM • • Industrial / General

HealthcareSpecialty & Generic PharmaSpecialty PharmaceuticalsOncology Therapeutics

AboutHUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in HongKong and internationally. It operates in Oncology/Immunology and Other Ventures segments. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and renal cell carcinoma, colorectal cancer (CRC), and gastric cancer (GC); and Fruquintinib, an inhibitor for CRC, breast cancer, GC, endometrial cancer (EMC), NSCLC, hepatocellular carcinoma, and gastrointestinal and solid tumors. It also develops Surufatinib, an inhibitor for neuroendocrine tumors (NET), pancreatic NET, non-pancreatic NET, biliary tract cancer, sarcoma, neuroendocrine neoplasm, esophageal cancer, small cell lung cancer, GC, thyroid cancer, EMC, NSCLC, and solid tumors; HMPL-523, a spleen tyrosine kinase inhibitor for hematological cancers and certain chronic immune diseases; and HMPL-689 for isoform PI3Kd (phosphoinositide 3'-kinase delta). In addition, it develops Tazemetostat, an inhibitor of EZH2 for the treatment of certain epithelioid sarcoma and follicular lymphoma patients; HMPL-306, an inhibitor for hematological malignancies, gliomas, and solid tumors; HMPL-760, an Bruton's tyrosine kinase inhibitor; HMPL-453, an inhibitor for intrahepatic cholangiocarcinoma; HMPL-295 for solid tumors; HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors; and Epitinib (HMPL-813) and Theliatinib (HMPL-309) inhibitors. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, BeiGene, Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. The company was incorporated in 2000 and is headquartered in Central, Hong Kong.Show more

Revenue $630M -24.8%
EBITDA -$31M -218.0%
Net Income $38M -62.6%
EPS (Diluted) 0.22 -63.3%
Gross Margin 44.64% -17.5%
EBITDA Margin -4.98% -256.9%
Operating Margin -6.94% -416.3%
Net Margin 5.99% -50.2%
ROE 4.98% -65.9%
ROIC -5.23% -270.1%
Debt/Equity 0.12 +0.4%
Interest Coverage -15.22 -162.9%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Strong 5Y sales CAGR of 25.2%

✗Weaknesses

✗Weak Piotroski F-Score: 3/9
✗Negative free cash flow
✗Low quality earnings: Net income not backed by cash flow

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y21.24%

5Y25.2%

3Y20.96%

TTM-1.41%

Profit (Net Income) CAGR

10Y21.52%

5Y-

3Y-

TTM1212.42%

EPS CAGR

10Y15.74%

5Y-

3Y-

TTM1151.59%

ROCE

10Y Avg-23.59%

5Y Avg-27.07%

3Y Avg-16.58%

Latest-4.93%

Peer Comparison

Oncology Therapeutics

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	Debt/Equity
HCMHUTCHMED (China) Limited	2.63B	15.31	69.59	-24.8%	77.53%	37.59%	0.12
SHPHShuttle Pharmaceuticals Holdings, Inc.	2.85M	1.48	-0.00			-7.68%	1.65
BGMSBio Green Med Solution, Inc.	7.01M	1.43	-0.00	-89.76%	-67.15%	-76.65%
SBFMSunshine Biopharma, Inc.	5.99M	1.22	-0.17	44.75%	-17.35%	-24.55%	0.04
RNTXRein Therapeutics Inc.	30.49M	1.16	-0.33			-127.48%
CGEMCullinan Therapeutics, Inc.	629.75M	10.66	-3.43			-48.03%	0.00
ONCBeOne Medicines Ltd.	34.44B	338.29	-55.28	54.96%	1.38%	1.66%	0.32

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	178.2M	216.08M	241.2M	214.11M	204.89M	227.98M	356.13M	426.41M	838M	630.2M
Revenue Growth %	0.94%	0.21%	0.12%	-0.11%	-0.04%	0.11%	0.56%	0.2%	0.97%	-0.25%
Cost of Goods Sold+	110.78M	156.33M	175.82M	143.94M	160.15M	188.52M	258.23M	311.1M	384.45M	348.88M
COGS % of Revenue	0.62%	0.72%	0.73%	0.67%	0.78%	0.83%	0.73%	0.73%	0.46%	0.55%
Gross Profit+	67.43M	59.75M	65.38M	70.17M	44.74M	39.46M	97.89M	115.31M	453.55M	281.32M
Gross Margin %	0.38%	0.28%	0.27%	0.33%	0.22%	0.17%	0.27%	0.27%	0.54%	0.45%
Gross Profit Growth %	2.41%	-0.11%	0.09%	0.07%	-0.36%	-0.12%	1.48%	0.18%	2.93%	-0.38%
Operating Expenses+	77.2M	106.59M	118.8M	161.01M	189.76M	236.13M	426.21M	523M	436.23M	321.93M
OpEx % of Revenue	0.43%	0.49%	0.49%	0.75%	0.93%	1.04%	1.2%	1.23%	0.52%	0.51%
Selling, General & Admin	29.83M	39.58M	43.28M	48.65M	52.93M	61.35M	127.13M	136.11M	133.18M	112.91M
SG&A % of Revenue	0.17%	0.18%	0.18%	0.23%	0.26%	0.27%	0.36%	0.32%	0.16%	0.18%
Research & Development	47.37M	66.87M	50.67M	78.82M	91.94M	111.23M	207.45M	267.59M	303.06M	213.37M
R&D % of Revenue	0.27%	0.31%	0.21%	0.37%	0.45%	0.49%	0.58%	0.63%	0.36%	0.34%
Other Operating Expenses	184K	609K	116K	-781K	44.88M	63.54M	91.64M	119.31M	0	-4.35M
Operating Income+	-9.77M	-46.7M	-53.42M	-92.64M	-145.02M	-198.62M	-344.29M	-409.77M	18.38M	-43.7M
Operating Margin %	-0.05%	-0.22%	-0.22%	-0.43%	-0.71%	-0.87%	-0.97%	-0.96%	0.02%	-0.07%
Operating Income Growth %	-2.21%	-3.78%	-0.14%	-0.73%	-0.57%	-0.37%	-0.73%	-0.19%	1.04%	-3.38%
EBITDA+	-7.76M	-44.39M	-50.84M	-89.05M	-140.08M	-192.56M	-337.1M	-401.11M	26.58M	-31.36M
EBITDA Margin %	-0.04%	-0.21%	-0.21%	-0.42%	-0.68%	-0.84%	-0.95%	-0.94%	0.03%	-0.05%
EBITDA Growth %	-1.83%	-4.72%	-0.15%	-0.75%	-0.57%	-0.37%	-0.75%	-0.19%	1.07%	-2.18%
D&A (Non-Cash Add-back)	2.02M	2.3M	2.58M	3.59M	4.94M	6.06M	7.19M	8.66M	8.21M	12.34M
EBIT	-9.14M	-45.7M	-52.08M	-85.65M	-140.07M	-188.95M	-215.15M	-409.77M	59.07M	1.76M
Net Interest Income+	-953K	-1.13M	-235K	4.97M	3.91M	2.45M	1.48M	8.95M	35.39M	37.21M
Interest Income	451K	502K	1.22M	5.98M	4.94M	3.24M	2.08M	9.6M	36.15M	40.08M
Interest Expense	1.4M	1.63M	1.46M	1.01M	1.03M	787K	592K	652K	759K	2.87M
Other Income/Expense	-767.49K	-659K	-119K	5.99M	5.28M	87.74M	188.96M	51.52M	87.23M	89.07M
Pretax Income+	-10.54M	-47.36M	-53.54M	-86.66M	-141.1M	-110.88M	-155.33M	-360.24M	105.6M	45.36M
Pretax Margin %	-0.06%	-0.22%	-0.22%	-0.4%	-0.69%	-0.49%	-0.44%	-0.84%	0.13%	0.07%
Income Tax+	1.6M	4.33M	3.08M	3.96M	3.27M	4.83M	11.92M	-283K	4.51M	7.19M
Effective Tax Rate %	-0.76%	-0.25%	0.5%	0.86%	0.73%	1.13%	1.25%	1%	0.95%	0.83%
Net Income+	7.99M	11.7M	-26.74M	-74.81M	-103.68M	-125.73M	-194.65M	-360.83M	100.78M	37.73M
Net Margin %	0.04%	0.05%	-0.11%	-0.35%	-0.51%	-0.55%	-0.55%	-0.85%	0.12%	0.06%
Net Income Growth %	0.49%	0.46%	-3.29%	-1.8%	-0.39%	-0.21%	-0.55%	-0.85%	1.28%	-0.63%
Net Income (Continuing)	10.43M	-51.66M	-22.96M	-71.29M	-103.68M	-115.52M	-167.04M	-360.39M	101.09M	38.17M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	18.92M	19.79M	23.23M	23.26M	24.89M	34.83M	52.62M	26.5M	12.85M	11.92M
EPS (Diluted)+	-0.32	0.10	-0.22	-0.55	-1.10	-0.90	-1.25	-2.15	0.60	0.22
EPS Growth %	-7.27%	1.31%	-3.2%	-1.5%	-1%	0.18%	-0.39%	-0.72%	1.28%	-0.63%
EPS (Basic)	-0.32	0.10	-0.22	-0.55	-1.10	-0.90	-1.25	-2.15	0.60	0.22
Diluted Shares Outstanding	109.32M	119.94M	123.43M	132.85M	133.14M	139.59M	158.54M	169.43M	173.84M	174.57M
Basic Shares Outstanding	109.32M	119.43M	123.43M	132.85M	133.14M	139.59M	158.54M	169.43M	169.93M	171.07M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	89.67M	167.38M	432.19M	370.54M	317.02M	530.74M	1.21B	839.89M	1.1B	1.07B
Cash & Short-Term Investments	31.94M	103.7M	358.3M	300.95M	217.17M	435.18M	1.01B	631M	886.34M	836.11M
Cash Only	31.94M	79.43M	85.27M	86.04M	121.16M	235.63M	377.54M	313.28M	283.59M	153.96M
Short-Term Investments	0	24.27M	273.03M	214.91M	96.01M	199.55M	634.16M	317.72M	602.75M	682.15M
Accounts Receivable	45.82M	48.93M	62.11M	43.85M	77.17M	47.87M	147.73M	126.72M	150.46M	167.74M
Days Sales Outstanding	93.84	82.65	93.99	74.75	137.48	76.64	151.41	108.47	65.53	97.15
Inventory	9.55M	12.82M	11.79M	12.31M	16.21M	19.77M	35.76M	56.69M	50.26M	50.4M
Days Inventory Outstanding	31.48	29.94	24.47	31.21	36.94	38.27	50.54	66.51	47.72	52.73
Other Current Assets	559K	610K	19.84M	8.33M	2.71M	20.89M	2.76M	3.15M	2.68M	3.3M
Total Non-Current Assets+	140.09M	175.06M	165.74M	161.58M	148.1M	193.38M	160.59M	189.56M	182.93M	207.64M
Property, Plant & Equipment	9.85M	11.17M	15.48M	17.79M	27.48M	45.31M	66.32M	84.67M	104.39M	97M
Fixed Asset Turnover	18.09x	19.34x	15.58x	12.04x	7.46x	5.03x	5.37x	5.04x	8.03x	6.50x
Goodwill	3.33M	3.14M	3.31M	3.19M	3.11M	3.31M	3.38M	3.14M	3.06M	2.99M
Intangible Assets	571K	469K	430K	347K	275K	227K	163K	3.22M	21K	0
Long-Term Investments	119.76M	158.51M	144.24M	-76.6M	2.93M	-60.04M	-557.68M	-243.94M	48.41M	-599.39M
Other Non-Current Assets	6.58M	1.77M	1.65M	216.27M	113.48M	203.06M	639M	327.1M	11.59M	707.04M
Total Assets+	229.75M	342.44M	597.93M	532.12M	465.12M	724.12M	1.37B	1.03B	1.28B	1.27B
Asset Turnover	0.78x	0.63x	0.40x	0.40x	0.44x	0.31x	0.26x	0.41x	0.65x	0.49x
Asset Growth %	0.05%	0.49%	0.75%	-0.11%	-0.13%	0.56%	0.9%	-0.25%	0.24%	-0%
Total Current Liabilities+	81.06M	95.12M	104.6M	85.48M	113.1M	158.4M	311.66M	353.9M	403.03M	376.56M
Accounts Payable	24.09M	35.54M	24.36M	25.63M	23.96M	31.61M	41.18M	71.11M	36.33M	42.52M
Days Payables Outstanding	79.36	82.98	50.58	64.98	54.61	61.21	58.2	83.44	34.49	44.49
Short-Term Debt	27.4M	19.96M	29.99M	432K	366K	3.19M	26.91M	0	31.16M	23.37M
Deferred Revenue (Current)	1000K	1000K	1000K	1000K	1000K	1000K	1000K	1000K	1000K	0
Other Current Liabilities	22.13M	9.31M	37.4M	48.17M	8.09M	-76K	40.95M	41.1M	228.93M	290.08M
Current Ratio	1.11x	1.76x	4.13x	4.33x	2.80x	3.35x	3.89x	2.37x	2.72x	2.83x
Quick Ratio	0.99x	1.62x	4.02x	4.19x	2.66x	3.23x	3.77x	2.21x	2.60x	2.70x
Cash Conversion Cycle	45.97	29.61	67.88	40.98	119.81	53.71	143.75	91.55	78.76	105.4
Total Non-Current Liabilities+	46.41M	43.26M	8.37M	34.38M	39.12M	46.77M	21.49M	38.67M	133.36M	125.78M
Long-Term Debt	26.77M	26.83M	579K	26.74M	26.82M	26.86M	0	18.1M	48.19M	59.43M
Capital Lease Obligations	9.15M	0	0	579K	3.05M	6.06M	7.16M	5.2M	2.86M	4.09M
Deferred Tax Liabilities	3.42M	4M	4.45M	4.84M	3.16M	5.06M	2.77M	2.71M	1.48M	2.99M
Other Non-Current Liabilities	10.6M	13.03M	538K	859K	5.96M	8.3M	14.33M	12.47M	11.35M	10.84M
Total Liabilities	127.48M	138.38M	112.97M	119.86M	152.22M	205.17M	333.15M	392.57M	536.39M	502.34M
Total Debt+	50M	46.79M	29.99M	26.74M	33.45M	38.9M	38.98M	27.01M	86.13M	89.82M
Net Debt	18.06M	-32.64M	-55.28M	-59.3M	-87.71M	-196.73M	-338.56M	-289.98M	-197.46M	-64.14M
Debt / Equity	0.49x	0.23x	0.06x	0.06x	0.11x	0.07x	0.04x	0.04x	0.12x	0.12x
Debt / EBITDA	-	-	-	-	-	-	-	-	3.24x	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-7.43x	-
Interest Coverage	-6.96x	-28.63x	-36.71x	-91.81x	-140.80x	-252.37x	-581.57x	-628.48x	24.21x	-15.22x
Total Equity+	102.28M	204.06M	484.97M	412.25M	312.9M	518.95M	1.04B	636.87M	743.39M	771.85M
Equity Growth %	-0.15%	1%	1.38%	-0.15%	-0.24%	0.66%	1%	-0.39%	0.17%	0.04%
Book Value per Share	0.94	1.70	3.93	3.10	2.35	3.72	6.56	3.76	4.28	4.42
Total Shareholders' Equity	83.36M	184.27M	461.73M	389M	288.01M	484.12M	986.89M	610.37M	730.54M	759.93M
Common Stock	56.53M	60.71M	66.45M	66.66M	66.69M	72.77M	86.45M	86.48M	87.13M	87.16M
Retained Earnings	-92.04M	-80.36M	-107.1M	-183M	-289.73M	-415.59M	-610.33M	-971.48M	-870.87M	-833.17M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	5.01M	-4.28M	5.43M	-243K	-3.85M	4.48M	5.57M	-1.9M	-8.16M	-11.59M
Minority Interest	18.92M	19.79M	23.23M	23.26M	24.89M	34.83M	52.62M	26.5M	12.85M	11.92M

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-9.38M	-9.57M	-8.94M	-32.85M	-80.91M	-62.07M	-204.22M	-268.6M	219.26M	497K
Operating CF Margin %	-0.05%	-0.04%	-0.04%	-0.15%	-0.39%	-0.27%	-0.57%	-0.63%	0.26%	0%
Operating CF Growth %	-1.7%	-0.02%	0.07%	-2.67%	-1.46%	0.23%	-2.29%	-0.32%	1.82%	-1%
Net Income	10.43M	14.56M	-22.96M	-71.29M	-103.68M	-115.52M	-167.04M	-360.39M	100.78M	37.73M
Depreciation & Amortization	2.02M	2.34M	2.58M	3.59M	4.94M	6.06M	7.19M	8.66M	8.21M	12.34M
Stock-Based Compensation	1.46M	3.44M	4.74M	10.13M	11.59M	19.64M	41.99M	30.59M	36.6M	21.61M
Deferred Taxes	-15.56M	-33.22M	20.82M	17.68M	-10.27M	552K	-115.14M	0	-102.76M	0
Other Non-Cash Items	2.5M	92K	147K	76K	394K	-2.08M	-3.68M	-6.17M	105.28M	-9.01M
Working Capital Changes	-10.23M	3.22M	-14.26M	6.96M	16.11M	29.27M	32.46M	58.7M	71.15M	-62.17M
Change in Receivables	-12.03M	-7.26M	2.74M	-459K	-553K	-4.69M	-35.63M	-14.45M	-21.34M	-41.57M
Change in Inventory	-5.15M	-3.43M	1.05M	-557K	-4.21M	-3.62M	-16M	-21.21M	4.13M	-772K
Change in Payables	3.66M	9.82M	-11.17M	1.26M	-1.66M	7.65M	9.56M	29.94M	-32.54M	6.2M
Cash from Investing+	8.86M	-33.6M	-260.78M	43.75M	119.03M	-125.44M	-306.32M	296.59M	-291.14M	-96.06M
Capital Expenditures	-3.32M	-4.33M	-5.02M	-6.36M	-8.56M	-19.58M	-16.76M	-36.66M	-32.61M	-17.93M
CapEx % of Revenue	0.02%	0.02%	0.02%	0.03%	0.04%	0.09%	0.05%	0.09%	0.04%	0.03%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-12.18M	-29.27M	-255.76M	50.12M	0	-2.33M	930K	16.49M	0	1.28M
Cash from Financing+	-5.47M	92.44M	273.2M	-8.23M	-1.49M	296.43M	650.03M	-82.76M	48.66M	-30.67M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	-99.74M	-87.44M	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	-480K	-14.47M	-1.59M	-3.57M	-965K	-9.63M	60.34M	61.75M	-9.07M	-1M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-12.71M	-13.9M	-13.96M	-39.21M	-89.48M	-81.65M	-220.98M	-305.26M	186.65M	-17.44M
FCF Margin %	-0.07%	-0.06%	-0.06%	-0.18%	-0.44%	-0.36%	-0.62%	-0.72%	0.22%	-0.03%
FCF Growth %	-2.32%	-0.09%	-0%	-1.81%	-1.28%	0.09%	-1.71%	-0.38%	1.61%	-1.09%
FCF per Share	-0.12	-0.12	-0.11	-0.30	-0.67	-0.58	-1.39	-1.80	1.07	-0.10
FCF Conversion (FCF/Net Income)	-1.17x	-0.82x	0.33x	0.44x	0.78x	0.49x	1.05x	0.74x	2.18x	0.01x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	7.2%	7.64%	-7.76%	-16.67%	-28.59%	-30.23%	-24.98%	-43.05%	14.6%	4.98%
Return on Invested Capital (ROIC)	-6.05%	-24.01%	-13.33%	-17.76%	-37.62%	-54.42%	-50.47%	-58.45%	3.07%	-5.23%
Gross Margin	37.84%	27.65%	27.11%	32.77%	21.84%	17.31%	27.49%	27.04%	54.12%	44.64%
Net Margin	4.49%	5.41%	-11.08%	-34.94%	-50.6%	-55.15%	-54.66%	-84.62%	12.03%	5.99%
Debt / Equity	0.49x	0.23x	0.06x	0.06x	0.11x	0.07x	0.04x	0.04x	0.12x	0.12x
Interest Coverage	-6.96x	-28.63x	-36.71x	-91.81x	-140.80x	-252.37x	-581.57x	-628.48x	24.21x	-15.22x
FCF Conversion	-1.17x	-0.82x	0.33x	0.44x	0.78x	0.49x	1.05x	0.74x	2.18x	0.01x
Revenue Growth	94.09%	21.25%	11.63%	-11.23%	-4.31%	11.27%	56.21%	19.73%	96.52%	-24.8%

Revenue by Segment

	2018	2019	2020	2021	2022	2023
Other Collaboration Licensing Revenue	12.13M	-	-	23.66M	14.95M	278.86M
Other Collaboration Licensing Revenue Growth	-	-	-	-	-36.80%	1764.75%
Collaboration Research And Development	17.68M	15.53M	9.77M	19M	23.74M	80.4M
Collaboration Research And Development Growth	-	-12.15%	-37.09%	94.40%	24.99%	238.64%
Commercialization Services	11.66M	2.58M	3.73M	27.43M	41.27M	48.61M
Commercialization Services Growth	-	-77.84%	44.50%	634.55%	50.48%	17.77%
Other Collaboration Royalties Revenue	261K	2.65M	4.89M	15.06M	26.31M	32.47M
Other Collaboration Royalties Revenue Growth	-	916.48%	84.32%	208.06%	74.65%	23.41%
Research And Development Services	7.83M	494K	491K	525K	507K	481K
Research And Development Services Growth	-	-93.69%	-0.61%	6.92%	-3.43%	-5.13%
Goods	-	-	-	266.2M	314.33M	-
Goods Growth	-	-	-	-	18.08%	-
Product	156.23M	175.99M	203.61M	-	-	-
Product Growth	-	12.65%	15.69%	-	-	-

Frequently Asked Questions

Valuation & Price

HUTCHMED (China) Limited (HCM) has a price-to-earnings (P/E) ratio of 69.6x. This suggests investors expect higher future growth.

Growth & Financials

HUTCHMED (China) Limited (HCM) reported $602.2M in revenue for fiscal year 2024. This represents a 261% increase from $166.9M in 2011.

HUTCHMED (China) Limited (HCM) saw revenue decline by 24.8% over the past year.

Yes, HUTCHMED (China) Limited (HCM) is profitable, generating $466.9M in net income for fiscal year 2024 (6.0% net margin).

Dividend & Returns

HUTCHMED (China) Limited (HCM) has a return on equity (ROE) of 5.0%. This is below average, suggesting room for improvement.

HUTCHMED (China) Limited (HCM) had negative free cash flow of $49.7M in fiscal year 2024, likely due to heavy capital investments.

US Stock Screener

...